Concord Drugs Ltd - 538965 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the year ended 31.03.202230-05-2022
30-05-2022
Concord Drugs Ltd - 538965 - Board Meeting Intimation for Audited Financial Results For The Quarter And Year Ended 31.03.2022
Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 ,inter alia, to consider and approve Audited financial results for the quarter and year ended 31.03.202217-05-2022
Concord Drugs Ltd - 538965 - Board Meeting Outcome for Resignation Of CS
Resignation of CS06-05-2022
Concord Drugs Ltd - 538965 - Disclosure Under Regulation 40(9) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
Disclosure under Regulation 40(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 201516-04-2022
Concord Drugs Ltd - 538965 - Compliance Under Regulation 7(3) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended 31.03.2022
Compliance under regulation 7(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for the financial year ended 31.03.202216-04-2022
Concord Drugs Ltd - 538965 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 201816-04-2022
Concord Drugs Ltd - 538965 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Jyoti GoyalDesignation :- Company Secretary and Compliance Officer16-04-2022
Concord Drugs Ltd - 538965 - Closure of Trading Window
Closure of trading window under SEBI (Prohibition of Insider Trading) Regulations, 201528-03-2022
Concord Drugs Ltd - 538965 - Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended 31.12.2021
unaudited financial results for the quarter ended 31.12.202114-02-2022